Successful Withdrawal from Dobutamine by Canagliflozin in a Diabetic Patient with Stage D Heart Failure
| Autor: | Shuji Joho, Tadakazu Hirai, Masaki Nakagaito, Makiko Nakamura, Ryuichi Ushijima, Koichiro Kinugawa |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Inotrope
medicine.medical_specialty Cardiotonic Agents medicine.medical_treatment Volume overload Tolvaptan 030204 cardiovascular system & hematology Diabetes Complications 03 medical and health sciences 0302 clinical medicine Dobutamine Internal medicine Diabetes mellitus Humans Hypoglycemic Agents Medicine 030212 general & internal medicine Canagliflozin Aged Heart Failure business.industry General Medicine medicine.disease Azosemide Cardiology Female Diuretic Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | International Heart Journal. 58:978-981 |
| ISSN: | 1349-3299 1349-2365 |
| DOI: | 10.1536/ihj.16-644 |
| Popis: | Patients with stage D heart failure (HF) frequently become dependent on high doses of diuretics and inotropic agents. Recently, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), an oral antidiabetic agent, has been demonstrated to have favorable effects in preventing HF. However, it remains unknown whether SGLT2i is reliable for patients with decompensated HF. We experienced a case of a patient with stage D HF for whom attempting intravenous dobutamine withdrawal was difficult even after the administration of all conventional pharmacological treatment. Administration of canagliflozin produced an additive diuretic action and correction of volume overload in combination with azosemide and tolvaptan, and resulted in successful withdrawal of dobutamine. Thus, SGLT2i might be promising for the treatment of patients with congestive HF who are refractory to conventional diuretic treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|